efficacy and tolerability of the new medication. There are no data to support a specific period of time for observation with pregnancy-compatible medications. Timing will vary depending on individual clinical factors; in clinical practice this is usually a minimum of several months. In women with RMD who are currently pregnant and have active disease that requires medical therapy, we strongly recommend initiating or continuing a pregnancycompatible steroid-sparing medication, as both active RMD and continuous high-dose glucocorticoid treatment have potential for maternal and fetal harm Pre-pregnancy or early pregnancy laboratory testing for relevant autoantibodies is recommended. Ascertaining anti-Ro/SSA, anti-La/SSB, and aPL status improves counseling regarding pregnancy and fetal risk. We strongly recommend testing for anti-Ro/SSA and anti-La/SSB once before or early in pregnancy in women with SLE or SLE-like disorders, Sj√∂gren's syndrome, systemic sclerosis, and rheumatoid